SSG
CABA icon

Summit Securities Group’s Cabaletta Bio CABA Stock Holding History

Summit Securities Group’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,824
Closed -$7.33K – 1060
2025
Q2 		$7.33K Buy
+4,824
New +$7.52K ﹤0.01% 931

Other funds holding CABA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

Summit Securities Group's CABA Position: Q3 2025 in Review

Summit Securities Group sold out of Cabaletta Bio (CABA) in Q3 2025, closing a stake of 4,824 shares — an estimated $7.33K sold.

Summit Securities Group first reported a position in CABA in Q2 2025 and held it in 1 quarter. The position peaked at $7.33K in Q2 2025. 75 funds tracked by Wall St. Rank hold CABA as of Q3 2025.

  • Summit Securities Group reported no remaining Cabaletta Bio position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 4,824 Cabaletta Bio shares in Q3 2025, an estimated $7.33K.
  • Summit Securities Group first reported a position in Cabaletta Bio in Q2 2025 and held it in 1 quarter.
  • Summit Securities Group's Cabaletta Bio position peaked at $7.33K in Q2 2025.
  • 75 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.